AYURCANN HOLDINGS CORP. (3ZQ0) - Net Assets

Latest as of September 2025: €-4.05 Million EUR ≈ $-4.74 Million USD

Based on the latest financial reports, AYURCANN HOLDINGS CORP. (3ZQ0) has net assets worth €-4.05 Million EUR (≈ $-4.74 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.39 Million ≈ $13.31 Million USD) and total liabilities (€15.44 Million ≈ $18.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 3ZQ0 current and long-term liabilities for a breakdown of total debt and financial obligations.

Key Net Assets Metrics

Metric Value
Current Net Assets €-4.05 Million
% of Total Assets -35.6%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 278.09

AYURCANN HOLDINGS CORP. - Net Assets Trend (2022–2025)

This chart illustrates how AYURCANN HOLDINGS CORP.'s net assets have evolved over time, based on quarterly financial data. Also explore 3ZQ0 total assets for the complete picture of this company's asset base.

Annual Net Assets for AYURCANN HOLDINGS CORP. (2022–2025)

The table below shows the annual net assets of AYURCANN HOLDINGS CORP. from 2022 to 2025. For live valuation and market cap data, see AYURCANN HOLDINGS CORP. (3ZQ0) total market value.

Year Net Assets Change
2025-06-30 €-2.95 Million
≈ $-3.45 Million
-651.70%
2024-06-30 €534.88K
≈ $625.33K
-80.13%
2023-06-30 €2.69 Million
≈ $3.15 Million
-44.98%
2022-06-30 €4.89 Million
≈ $5.72 Million
--

Equity Component Analysis

This analysis shows how different components contribute to AYURCANN HOLDINGS CORP.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 1276064700.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Other Components €14.91 Million %
Total Equity €-2.95 Million 100.00%

AYURCANN HOLDINGS CORP. Competitors by Market Cap

The table below lists competitors of AYURCANN HOLDINGS CORP. ranked by their market capitalization.

Company Market Cap
Tandem Group
LSE:TND
$114.13K
Shearwater Group plc
LSE:SWG
$115.38K
Dosni Roha Indonesia Tbk PT
JK:ZBRA
$117.43K
Sound Energy PLC
LSE:SOU
$118.07K
Croma Security Solutions Group Plc
LSE:CSSG
$113.08K
Celadon Pharmaceuticals PLC
LSE:CEL
$112.25K
LIFT GLOBAL VENT. LS-01
F:7XO
$111.90K
Induction Healthcare Group PLC
LSE:INHC
$111.33K

Equity Growth Attribution

This analysis shows how different factors contributed to changes in AYURCANN HOLDINGS CORP.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 534,878 to -2,950,906, a change of -3,485,784 (-651.7%).
  • Net loss of 3,485,784 reduced equity.
  • Other factors decreased equity by 0.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €-3.49 Million -118.13%
Total Change €- -651.70%

Book Value vs Market Value Analysis

This analysis compares AYURCANN HOLDINGS CORP.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2022-06-30 €0.04 €0.00 x
2023-06-30 €0.02 €0.00 x
2024-06-30 €0.00 €0.00 x
2025-06-30 €-0.02 €0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently AYURCANN HOLDINGS CORP. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -11.20%
  • • Asset Turnover: 2.45x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-250.50%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2022 -63.10% -32.90% 1.29x 1.49x €-3.58 Million
2023 -197.11% -42.48% 0.98x 4.73x €-5.58 Million
2024 -741.80% -15.77% 1.69x 27.77x €-4.02 Million
2025 0.00% -11.20% 2.45x 0.00x €-3.19 Million

Industry Comparison

This section compares AYURCANN HOLDINGS CORP.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $865,108,614
  • Average return on equity (ROE) among peers: -8.78%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
AYURCANN HOLDINGS CORP. (3ZQ0) €-4.05 Million -63.10% N/A $113.81K
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) $6.51 Billion 11.81% 0.39x $635.99 Million
LORDS CO. WORLDW. HOLD. (4XM) $-1.01 Million 0.00% 0.00x $134.78K
EQL PHARMA AB (7JK) $154.75 Million 19.98% 0.85x $148.83 Million
Alkermes plc (8AK) $1.07 Billion 1.94% 0.48x $5.00 Billion
OPTIMI HEALTH CORP. (8BN) $9.58 Million -63.03% 0.52x $17.99 Million
LABIANA HEALTH S.A.EO-10 (8RK) $2.57 Million 9.87% 19.25x $40.60 Million
CANNABIS POLAND AB ZY-10 (8TE) $3.54 Million -57.78% 0.18x $1.75 Million
Apontis Pharma AG (APPH) $40.71 Million -1.83% 0.33x $91.63 Million
CRAFTPORT CANNABIS CORP. (BBW0) $-3.18 Million 0.00% 0.00x $1.45 Million

About AYURCANN HOLDINGS CORP.

F:3ZQ0 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$113.81K
€97.35K EUR
Market Cap Rank
#30945 Global
#2788 in Germany
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.02
All Time High
€0.18
About

Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products. The company sells product under the Fuego, H&S, and XPL… Read more